These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 27465879)

  • 41. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Deeks ED
    Drugs; 2018 Jul; 78(10):1013-1024. PubMed ID: 29915897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
    Margot NA; Wong P; Kulkarni R; White K; Porter D; Abram ME; Callebaut C; Miller MD
    J Infect Dis; 2017 Mar; 215(6):920-927. PubMed ID: 28453836
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
    Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
    Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
    Raffi F; Orkin C; Clarke A; Slama L; Gallant J; Daar E; Henry K; Santana-Bagur J; Stein DK; Bellos N; Scarsella A; Yan M; Abram ME; Cheng A; Rhee MS
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):226-231. PubMed ID: 28272164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
    Ray AS; Fordyce MW; Hitchcock MJ
    Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.
    Wang H; Lu X; Yang X; Xu N
    Medicine (Baltimore); 2016 Oct; 95(41):e5146. PubMed ID: 27741146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
    Negredo E; Clotet B
    Expert Opin Pharmacother; 2018 Jun; 19(8):929-934. PubMed ID: 29767543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
    Gomez M; Seybold U; Roider J; Härter G; Bogner JR
    Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
    J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tenofovir alafenamide fumarate for the treatment of HIV infection.
    Sampath R; Zeuli J; Rizza S; Temesgen Z
    Drugs Today (Barc); 2016 Nov; 52(11):617-625. PubMed ID: 28112280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide.
    Wassner C; Bradley N; Lee Y
    J Int Assoc Provid AIDS Care; 2020; 19():2325958220919231. PubMed ID: 32295453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
    Viganò M; Loglio A; Grossi G; Lampertico P
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):153-161. PubMed ID: 29338458
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.
    Tabak F; Zerdali E; Altuntaş O; Gunduz A; Bolukcu S; Mete B; Nakir IY; Kumbasar Karaosmanoglu H; Yildiz DS; Meric Koc M; Dokmetas İ;
    Int J STD AIDS; 2021 May; 32(6):562-569. PubMed ID: 33599173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
    Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
    Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
    Hill A; Hughes SL; Gotham D; Pozniak AL
    J Virus Erad; 2018 Apr; 4(2):72-79. PubMed ID: 29682298
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
    Surial B; Cavassini M; Calmy A; Fehr J; Stöckle M; Bernasconi E; Roth B; Fux CA; Kovari H; Furrer H; Rauch A; Wandeler G;
    BMC Infect Dis; 2019 Oct; 19(1):834. PubMed ID: 31601174
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
    Shafran SD; Di Perri G; Esser S; Lelièvre JD; Parczewski M
    HIV Med; 2019 Jun; 20 Suppl 7():1-16. PubMed ID: 31099116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
    Mesplède T
    Expert Opin Pharmacother; 2021 Jul; 22(10):1245-1251. PubMed ID: 33691554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
    Ma Q; Ocque AJ; Morse GD; Sanders C; Burgi A; Little SJ; Letendre SL
    Clin Infect Dis; 2020 Aug; 71(4):982-988. PubMed ID: 31560741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.